Durvalumab for the Treatment of Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Review Group ◽

Unresectable Stage ◽

Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0720-8 ◽

2018 ◽

Vol 37 (5) ◽

pp. 645-654 ◽

Cited By ~ 1

Author(s):

Lindsay Claxton ◽

Joanne O’Connor ◽

Nerys Woolacott ◽

Kath Wright ◽

Robert Hodgson

Keyword(s):

Lung Cancer ◽

Evidence Review Group ◽

Small Cell ◽

Technology Appraisal ◽

Small Cell Lung ◽

Review Group ◽

Anaplastic Lymphoma ◽

Group Evaluation ◽

Crizotinib for Untreated Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-017-0497-1 ◽

2017 ◽

Vol 35 (9) ◽

pp. 909-919 ◽

Cited By ~ 3

Author(s):

Philip Morgan ◽

Nerys Woolacott ◽

Mousumi Biswas ◽

Teumzghi Mebrahtu ◽

Melissa Harden ◽

...

Keyword(s):

Lung Cancer ◽

Anaplastic Lymphoma Kinase ◽

Evidence Review Group ◽

Small Cell ◽

Technology Appraisal ◽

Small Cell Lung ◽

Review Group ◽

Anaplastic Lymphoma ◽

Correction to: Ceritinib for Untreated Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung: An Evidence Review Group Evaluation of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0743-1 ◽

2018 ◽

Vol 37 (5) ◽

pp. 739-739

Author(s):

Lindsay Claxton ◽

Joanne O’Connor ◽

Nerys Woolacott ◽

Kath Wright ◽

Robert Hodgson

Keyword(s):

Anaplastic Lymphoma Kinase ◽

Evidence Review Group ◽

Small Cell ◽

Technology Appraisal ◽

Small Cell Lung ◽

Review Group ◽

Anaplastic Lymphoma ◽

Group Evaluation ◽

Fulvestrant for Untreated Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0725-3 ◽

2018 ◽

Vol 37 (6) ◽

pp. 753-762

Author(s):

Joanna Picot ◽

Neelam Kalita ◽

Wendy Gaisford ◽

Petra Harris ◽

Oluchukwu Onyimadu ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Hormone Receptor Positive ◽

Trastuzumab Emtansine for Treating HER2-Positive, Unresectable, Locally Advanced or Metastatic Breast Cancer After Treatment with Trastuzumab and a Taxane: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-016-0386-z ◽

2016 ◽

Vol 34 (7) ◽

pp. 673-680 ◽

Cited By ~ 6

Author(s):

Hazel Squires ◽

Matt Stevenson ◽

Emma Simpson ◽

Rebecca Harvey ◽

John Stevens

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Evidence Review Group ◽

Technology Appraisal ◽

Trastuzumab Emtansine ◽

Her2 Positive ◽

Review Group ◽

Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics - Open ◽

10.1007/s41669-018-0114-z ◽

2019 ◽

Vol 3 (3) ◽

pp. 293-302

Author(s):

Nigel Fleeman ◽

Adrian Bagust ◽

Rui Duarte ◽

Marty Richardson ◽

Sarah Nevitt ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Chemotherapy Regimen ◽

Locally Advanced ◽

Metastatic Breast ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Pembrolizumab for Locally Advanced or Metastatic Urothelial Cancer Where Cisplatin is Unsuitable: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0750-2 ◽

2018 ◽

Vol 37 (9) ◽

pp. 1073-1080 ◽

Cited By ~ 1

Author(s):

Shijie Ren ◽

Hazel Squires ◽

Emma Hock ◽

Eva Kaltenthaler ◽

Andrew Rawdin ◽

...

Keyword(s):

Urothelial Cancer ◽

Locally Advanced ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Metastatic Urothelial Cancer ◽

Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-018-0708-4 ◽

2018 ◽

Vol 37 (2) ◽

pp. 141-153 ◽

Cited By ~ 4

Author(s):

Nasuh C. Büyükkaramikli ◽

Saskia de Groot ◽

Rob Riemsma ◽

Debra Fayter ◽

Nigel Armstrong ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast Cancer ◽

Aromatase Inhibitor ◽

Locally Advanced ◽

Metastatic Breast ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Vedolizumab for Treating Moderately to Severely Active Crohn’s Disease After Prior Therapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

PharmacoEconomics ◽

10.1007/s40273-016-0436-6 ◽

2016 ◽

Vol 34 (12) ◽

pp. 1241-1253 ◽

Cited By ~ 5

Author(s):

Rachid Rafia ◽

Alison Scope ◽

Sue Harnan ◽

John W. Stevens ◽

Matt Stevenson ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽

Prior Therapy ◽

Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective

PharmacoEconomics ◽

10.1007/s40273-015-0296-5 ◽

2015 ◽

Vol 33 (11) ◽

pp. 1187-1194 ◽

Cited By ~ 11

Author(s):

Emma L. Simpson ◽

Sarah Davis ◽

Praveen Thokala ◽

Penny R. Breeze ◽

Peter Bryden ◽

...

Keyword(s):

Prostate Cancer ◽

Evidence Review Group ◽

Technology Appraisal ◽

Review Group ◽